Siegfried Reaches ‘Next Level’ As Sales And Profits Lift
Company To Execute On COVID-19 Vaccine Partnership With BioNTech
Swiss company Siegfried has seen an increase in sales, EBITDA and net profit in 2020 and expects its turnover to exceed CHF1bn this year. The firm is also looking to execute on its partnership with BioNTech on filling and packaging the firm’s COVID-19 vaccine.
You may also be interested in...
Siegfried has completed the acquisition of two Spanish manufacturing facilities from Novartis, in a move that will significantly enhance the Swiss CDMO’s capacity.
After making several targeted investments aimed at enhancing its global production network, Siegfried has announced the acquisition of two manufacturing sites from Novartis in Spain. With this acquisition, the Swiss contract development and manufacturing organization is looking to create opportunities for profitable growth and achieve “critical size.”
The Advancing Education on Biosimilars Act and the Ensuring Innovation Act will be looked at by the US President Joe Biden, after receiving the approval of both the Senate and the House of Representatives. The bills are aimed at lowering prescription drug costs and saving overall healthcare costs.